Loading
Japanese hepatologist who led REFLECT, the trial that made lenvatinib a first-line option for liver cancer.
Masatoshi Kudo (Kindai University, Osaka) was principal investigator of REFLECT, which showed lenvatinib is non-inferior to sorafenib in unresectable hepatocellular carcinoma and became the first new first-line option in a decade. He has published extensively on combining systemic therapy with transarterial chemoembolisation and edits the journal Liver Cancer. He continues to lead HCC trials across Asia.
| Title | Journal | Year |
|---|---|---|
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (REFLECT) | Lancet | 2018 |
| Lenvatinib plus transarterial chemoembolization for unresectable hepatocellular carcinoma (LAUNCH) | JCO | 2023 |
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma, Small-molecule kinase inhibitors and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares REFLECT, Hepatocellular carcinoma and the tag hcc.
Shares Small-molecule kinase inhibitors and the tag trialist.